United Therapeutics Builds a Moat Around Lung Transplants

United Therapeutics’ (NASDAQ: UTHR) FDA‑approved lung perfusion platform is an organ‑supply expansion story that supports the company’s broader lung‑transplant and xenotransplantation strategy, rather than a near‑term revenue driver on the level of Tyvaso. It deepens UT’s role as core infrastructure in lung transplantation, creating a differentiated, defensible position around the procedure itself.

Investor framing

United’s ex vivo lung perfusion (EVLP) system allows the company to participate economically in each lung transplant through perfusion services and logistics, not just through drugs. With full FDA approval and removal of prior volume caps, the technology can move from a humanitarian niche to broader clinical use as centers adopt EVLP into their workflows.

Clinically acceptable one‑year survival data help support reimbursement and ease safety concerns, which is key for payer uptake and real‑world growth. While the revenue contribution is likely modest in the near term, every incremental transplant supported by EVLP also expands the addressable market for UT’s pulmonary therapies.

Strategic angle

EVLP fits neatly into United’s long‑term vision of an integrated lung‑care ecosystem that spans PAH drugs, transplant infrastructure, and eventually manufactured or xenogeneic organs. By operating centralized perfusion labs via its Lung Bioengineering subsidiary, United can build a recurring, procedure‑linked service business with potential operating leverage as volumes scale.

Once transplant programs are architected around UT’s platform—clinically, operationally, and contractually—switching costs rise, reinforcing competitive moat and long‑term strategic optionality. Over time, this infrastructure positions United as the default partner for future innovations in donor‑lung optimization and advanced transplant technologies.